distribution agreement

Ginkgo will offer Access Bio's antigen tests through its Concentric by Ginkgo service.

The system, which automates the process of performing blood cell differentials, was cleared by the US Food and Drug Administration last month.

The agreement covers Proprietary Innovation's line of SARS-CoV-2 assays including its lateral flow chromatographic-based antibody and antigen tests.

Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.

Kantaro said that authorized clinical testing laboratories in Europe can use its enzyme-linked immunoassays, which detect IgG antibodies to two coronavirus antigens.

The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.

PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.

The test uses real-time reverse transcription loop-mediated isothermal amplification to detect the SARS-CoV-2 N gene, according to CellSafe.

The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.

Baxter will distribute BioMérieux's Nephroclear CCL14 diagnostic in Europe and the US following regulatory approval and launch in those markets.